Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666087 | 0.89 | PARK7 (0.64) | PARK7KMT2AMEN1POLBKDM4E | |
| SCHEMBL167099 | 0.88 | PARK7 (0.50) | PARK7KMT2AMEN1POLBKDM4E | |
| SCHEMBL666669 | 0.87 | PARK7 (0.53) | PARK7KMT2AMEN1POLBKDM4E | |
| SCHEMBL664798 | 0.85 | PARK7 (0.56) | PARK7KMT2AMEN1POLBKDM4E | |
| SCHEMBL352080 | 0.79 | PARK7 (0.51) | PARK7KMT2AMEN1POLBMAPT | |
| SCHEMBL665474 | 0.78 | PARK7 (0.49) | PARK7KMT2AMEN1POLBKDM4E | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1669417 | 0.77 | PARK7 (0.54) | PARK7KMT2AMEN1POLBKDM4E | |
| Dehydroxymethylepoxyquinomicin SCHEMBL1671089 | 0.77 | PARK7 (0.54) | PARK7KMT2AMEN1POLBKDM4E | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14504317 | 0.77 | PARK7 (0.54) | PARK7KMT2AMEN1POLBKDM4E | |
| Dehydroxymethylepoxyquinomicin SCHEMBL14491796 | 0.77 | PARK7 (0.54) | PARK7KMT2AMEN1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | claimed |
| EP-2424850-A1 | BENZAMIDE AND NAPHTHAMIDE DERIVATIVES INHIBITING NUCLEAR FACTOR- KAP PA (B) - (NF-KB) | Profectus Biosciences, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | PROFECTUS BIOSCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010127058-A1 | BENZAMIDE AND NAPHTHAMIDE DERIVATIVES INHIBITING NUCLEAR FACTOR- KAP PA (B) - (NF-KB) | PROFECTUS BIOSCIENCES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046357-A1 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) | NFKBIA, IKBKB, NFKB1 | PARK7 3384/4885KMT2A 468/4885MEN1 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.